NCT00460941View on ClinicalTrials.gov

A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.

PHASE2CompletedINTERVENTIONAL

Enrollment

133

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

Diabetes Mellitus Type 2

Interventions

DRUG

Placebo

sc weekly

DRUG

Taspoglutide 20mg

sc weekly

DRUG

Taspoglutide 20mg-30mg

sc weekly

DRUG

Taspoglutide 20mg-40mg

sc weekly

Trial Locations (29)

10

Lima

31

Lima

2050

Camperdown

5000

Adelaide

10115

Berlin

11108

Narbonne

20783

Hyattsville

23294

Richmond

25030

Besançon

27103

Winston-Salem

31238

Chihuahua City

32216

Jacksonville

41460

Neuss

42431

Madisonville

64410

Monterrey

71913

Hot Springs

72401

Jonesboro

72432

Harrisburg

75230

Dallas

75231

Dallas

75877

Paris

80020

Culiacán

80636

München

86021

Poitiers

89109

Tampico

91106

Corbeil-Essonnes

91950

National City

LIMA 29

Lima

00716

Ponce

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT00460941 - A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin. | Biotech Hunter | Biotech Hunter